Gilead Reports Promising Veklury Mortality Data

Real-world data involving Gilead Sciences’ Veklury (remdesivir) show that the therapy offered a lower mortality risk in hospitalized Covid-19 patients. Data from three retrospective real-world data studies show a reduction in mortality was “observed across a spectrum of baseline oxygen requirements,” the company says.

For example, one study based on claims data from HealthVerity, performed in collaboration with Aetion, assessed mortality and the likelihood of discharge in hospitalized Covid-19 patients who were treated with Veklury (n=24,856) versus matched controls (n=24,856) between 5/2020 and 5/2021 found that patients receiving Veklury had a statistically significant 23% lower mortality risk compared with controls, Gilead says. Overall, it found a significantly greater likelihood of discharge by Day 28 in patients completing a full five-day Veklury treatment compared with controls.